(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.04%) $0.927
(0.26%) $10.87
(0.05%) $0.793
(-0.29%) $92.31
@ $19.46
Issued: 14 Feb 2024 @ 09:30
Return: 13.72%
Previous signal: Feb 13 - 09:31
Previous signal:
Return: -3.52 %
Live Chart Being Loaded With Signals
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases...
Stats | |
---|---|
Today's Volume | 499 971 |
Average Volume | 739 113 |
Market Cap | 1.35B |
EPS | $0 ( 2024-02-27 ) |
Next earnings date | ( $-0.0900 ) 2024-05-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.64 |
ATR14 | $0.0180 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | Kuch John J | Sell | 849 | Common Stock |
2024-03-11 | Eckert Celia | Sell | 850 | Common Stock |
2024-03-11 | Desjarlais John R | Sell | 1 280 | Common Stock |
2024-03-11 | Dahiyat Bassil I | Sell | 2 741 | Common Stock |
2024-03-06 | Gustafson Kurt A | Buy | 15 000 | Common Stock |
INSIDER POWER |
---|
62.14 |
Last 97 transactions |
Buy: 2 670 677 | Sell: 459 713 |
Volume Correlation
Xencor Inc Correlation
10 Most Positive Correlations | |
---|---|
THRX | 0.898 |
WDC | 0.891 |
PALT | 0.886 |
TREE | 0.883 |
OZKAP | 0.882 |
OTRK | 0.881 |
XPEL | 0.873 |
HLMN | 0.871 |
MBIO | 0.869 |
TCBIO | 0.862 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Xencor Inc Correlation - Currency/Commodity
Xencor Inc Financials
Annual | 2023 |
Revenue: | $168.34M |
Gross Profit: | $156.84M (93.17 %) |
EPS: | $-2.08 |
Q4 | 2023 |
Revenue: | $44.69M |
Gross Profit: | $41.46M (92.78 %) |
EPS: | $-0.310 |
Q3 | 2023 |
Revenue: | $59.16M |
Gross Profit: | $56.02M (94.69 %) |
EPS: | $-0.400 |
Q2 | 2023 |
Revenue: | $45.52M |
Gross Profit: | $42.64M (93.66 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
Xencor Inc
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators